Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood.
The effects of tiagabine (TGB) on abilities and on adjustment and mood are as yet incompletely understood. These effects were compared with those of phenytoin (PHT) and carbamazepine (CBZ) in an add-on study. Patients included in the analysis were adults with uncontrolled partial seizures who at study entry were on CBZ alone (n=153) or on PHT alone (n=124). Of the patients receiving CBZ, 82 were randomized to add-on TGB and 71 were randomized to add-on PHT during the double-blind period. Of the patients receiving PHT, 58 were randomized to add-on TGB and 66 were randomized to add-on CBZ. Eight tests of mental abilities and three of mood and adjustment were given prior to assignment of add-on treatment and after up to 16 weeks of add-on treatment. For the baseline CBZ group, analyses were done to search for differential changes from baseline in the test scores of the add-on TGB and add-on PHT groups, and for the baseline PHT group in the add-on TGB and add-on CBZ groups. In the baseline CBZ group, no differences in test scores were found between PHT and TGB. In the baseline PHT group for the area of abilities, patients treated with TGB had improved verbal fluency, as well as quicker responses on a test of perceptual/motor speed compared with patients treated with CBZ. For the baseline PHT group in the area of adjustment and mood, patients treated with TGB reported less positive mood and more financial concerns compared to patients treated with CBZ. Overall, add-on TGB showed few or no differences in comparison with add-on CBZ and add-on PHT.
Dodrill
C B
CB
Regional Epilepsy Center, Departments of Neurology and Neurological Surgery, University of Washington School of Medicine, Seattle, WA, USA. cdodrill@u.washington.edu
Arnett
J L
JL
Deaton
R
R
Lenz
G T
GT
Sommerville
K W
KW
D000223:Adaptation, Psychological / Q000187:drug effects; D000328:Adult; D000339:Affect / Q000187:drug effects; D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D002220:Carbamazepine / Q000494:pharmacology* / Q000627:therapeutic use; D003071:Cognition / Q000187:drug effects; D004311:Double-Blind Method; D017029:Epilepsy, Complex Partial / Q000188:drug therapy / Q000523:psychology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009557:Nipecotic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D010672:Phenytoin / Q000494:pharmacology* / Q000627:therapeutic use; D018709:Statistics, Nonparametric; D000078308:Tiagabine
D000927:Anticonvulsants; D009557:Nipecotic Acids; D002220:Carbamazepine; D010672:Phenytoin; D000078308:Tiagabine